Epizyme, Inc.
CREBBP RELATED CANCER THERAPY
Last updated:
Abstract:
The present disclosure provides novel cancer therapies. The treatment of cancers harboring EP300 mutations with CREBBP inhibition therapy is described.
Status:
Application
Type:
Utility
Filling date:
25 Jul 2017
Issue date:
5 Sep 2019